Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR A2009

Next Previous
X
Search
Drug Profile

SHR A2009

Alternative Names: SHR-A2009

Latest Information Update: 21 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 19 Jun 2024 Henan Cancer Hospital plans a phase II trial in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) in June 2024 (NCT06465238)
  • 25 Jan 2024 Shandong Suncadia Medicine plans a phase I/II trial for Breast cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy, Combination therapy) in January 2024 (IV) (NCT06222879)
  • 28 Nov 2023 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease) (IV), prior to November 2023 (Jiangsu HengRui Medicine pipeline, June 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top